Shots:
- Ipsen has entered into a definitive merger agreement to acquire Kartos Therapeutics, incl. its asset, navtemadlin, expanding its hemato-oncology late-stage pipeline
- As per the deal, Ipsen will acquire Kartos Therapeutics through a fully-owned subsidiary for $450M upfront & ~$1.3B in milestones, incl. a significant regulatory approval milestone & sales-based milestones; closing is expected by the end of Q3’26
- Navtemadlin, an oral MDM2 inhibitor, is being evaluated in the global P-III (POIESIS) trial (n>600) as an add-on therapy to ruxolitinib in pts with intermediate & high-risk TP53wt myelofibrosis who have a suboptimal response to ruxolitinib, with topline data expected in 2027
Ref: Globenewswire | Image: Kartos | Press Release
Related News: Ipsen’s Ojemda (Tovorafenib) Receives Conditional Approval for R/R BRAF-Altered Pediatric Low-Grade Glioma (pLGG) in the EU
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
